- Conditions
- HIV Infections
- Interventions
- PrEP
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 40
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV, STI
- Interventions
- PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP
- Behavioral · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- PrEP Adherence Monitoring
- Interventions
- tenofovir disoproxil and emtricitabine
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Newark, New Jersey + 1 more
- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 3,292 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
- Conditions
- HIV/AIDS
- Interventions
- Genvoya
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infection
- Interventions
- Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- HIV, Prophylaxis, Transgender
- Interventions
- Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg, Truvada plus Estradiol 6 mg, Estradiol 6 mg alone
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV Infection
- Interventions
- 3MV, PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
- Behavioral · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 22 Years · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
- Conditions
- HIV Infections
- Interventions
- Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Timeline
- 2026 – 2029
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more
- Conditions
- HIV Infections
- Interventions
- Daily dosing, Time-driven dosing, Event-driven dosing
- Drug
- Lead sponsor
- HIV Prevention Trials Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infection
- Interventions
- Emtricitabine/tenofovir disoproxil
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 15 Years to 22 Years · Male only
- Enrollment
- 167 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
- Conditions
- HIV Infections
- Interventions
- FTC 200 mg/TDF 300 mg fixed-dose combination tablet
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 557 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
- Conditions
- HIV
- Interventions
- Upper endoscopy, Anoscopy, Truvada
- Procedure · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- HIV
- Interventions
- Condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Pre-exposure prophylaxis with FTC/TDF, Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care
- Behavioral · Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Baltimore, Maryland
- Conditions
- HIV Pre-exposure Prophylaxis, PrEP
- Interventions
- PrEP Uptake with Rapid Start, Pre-Exposure Prophylaxis (PrEP) Persistence
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV
- Interventions
- Truvada, Gel lubricant
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Decatur, Georgia